E-viri
Recenzirano
Odprti dostop
-
Roszkowska, Katarzyna A.; Piecuch, Aleksandra; Sady, Maria; Gajewski, Zdzisław; Flis, Sylwia
International journal of molecular sciences, 11/2022, Letnik: 23, Številka: 21Journal Article
Continuous development of personalized treatments is undoubtedly beneficial for oncogenic patients’ comfort and survival rate. Mutant TP53 is associated with a worse prognosis due to the occurrence of metastases, increased chemoresistance, and tumor growth. Currently, numerous compounds capable of p53 reactivation or the destabilization of mutant p53 are being investigated. Several of them, APR-246, COTI-2, SAHA, and PEITC, were approved for clinical trials. This review focuses on these novel therapeutic opportunities, their mechanisms of action, and their significance for potential medical application.
